Evaluating the Impact of Guidelines on Physician Prescription Practices in Chronic Kidney Disease
评估慢性肾脏病医生处方实践指南的影响
基本信息
- 批准号:9975628
- 负责人:
- 金额:$ 7.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAmericanAmerican Heart AssociationAtherosclerosisAwarenessBehaviorBiometryCaliforniaCardiologyCardiovascular DiseasesCardiovascular systemCaringChronic Kidney FailureClinical Practice GuidelineClinical ResearchCross-Sectional StudiesDataData SetDatabasesDevelopmentElectronic Health RecordElementsEnrollmentEquationEvaluationEventEvidence based treatmentFibrinogenFrequenciesFundingGeneral PopulationGlomerular Filtration RateGoalsGuidelinesHealthHealth systemHealthcare SystemsHydroxymethylglutaryl-CoA Reductase InhibitorsIndividualInstructionInterruptionInterventionK-Series Research Career ProgramsKidneyKidney DiseasesKnowledgeLipidsMorbidity - disease rateNational Health and Nutrition Examination SurveyNephrologyOutcomePatient CarePatientsPerceptionPhysiciansPopulationPrevalencePreventivePrimary Health CareProviderPublic HealthPublishingRecommendationResearch DesignRisk AssessmentRisk ManagementRisk ReductionSan FranciscoScienceSerumSocietiesSurvey MethodologySurveysSystemTime Series AnalysisTime trendUniversitiesUpdateVisitbasecardiovascular disorder riskcardiovascular risk factorcare deliverycare providerscohortcollegedesigneffective interventionevidence basehealth care deliveryimplementation strategyimprovedinsightlow socioeconomic statusmedical specialtiesmortalitypopulation basedprogramsresearch study
项目摘要
ABSTRACT
Cardiovascular disease is the leading cause of morbidity and mortality among individuals with chronic kidney
disease (CKD). Despite evidence and clinical practice guidelines supporting the use of statins for
cardiovascular risk reduction in non-dialysis requiring chronic kidney disease, prevalence of statin prescription
among individuals with CKD remains low. Strategies to increase statin use represent an important opportunity
to improve cardiovascular outcomes for this population. Reasons underlying the current low rates of statin use
remain unclear, thus elucidating these reasons will be important for informing the design of successful
implementation strategies.
The specific aims of this proposal are intended to examine different factors that influence rates of statin
prescription among individuals with CKD. Aim 1 will assess the impact of changes in clinical practice guidelines
by examining temporal trends in statin use among individuals with CKD using a nationally representative
database. Aims 2 and 3 will examine more granular provider-level factors that may influence statin prescription
(i.e., the contribution of nephrology care to cardiovascular risk management, primary care provider (PCP)
knowledge of preventive cardiovascular care guidelines, PCP perception of cardiovascular risk in CKD
patients) and correlate them with individual practice behaviors, using data from the San Francisco Health
Network, a local public health system that disproportionately cares for individuals of low socioeconomic status.
The study design will involve cross-sectional analyses of both a large national dataset (the National Health and
Nutrition Examination Survey; NHANES) for Aim 1 and a local dataset from the electronic health record of one
health delivery system (San Francisco Health Network) for Aims 2 and 3. Aim 3 will also involve a survey of
local primary care providers to assess awareness of guidelines and perceptions of cardiovascular risk pertinent
to CKD patients.
抽象的
心血管疾病是慢性肾病患者发病和死亡的主要原因
疾病(CKD)。尽管有证据和临床实践指南支持使用他汀类药物
不需要透析的慢性肾病患者的心血管风险降低,他汀类药物处方的普及
慢性肾病患者的患病率仍然很低。增加他汀类药物使用的策略是一个重要的机会
改善该人群的心血管结局。目前他汀类药物使用率低的原因
仍不清楚,因此阐明这些原因对于指导成功的设计非常重要
实施策略。
该提案的具体目的是检查影响他汀类药物使用率的不同因素
慢性肾病患者的处方。目标 1 将评估临床实践指南变化的影响
通过使用全国代表检查 CKD 患者他汀类药物使用的时间趋势
数据库。目标 2 和 3 将检查可能影响他汀类药物处方的更细粒度的提供者层面的因素
(即肾科护理对心血管风险管理的贡献、初级保健提供者 (PCP)
预防性心血管护理指南的知识、PCP 对 CKD 心血管风险的认知
患者),并使用来自旧金山健康中心的数据将其与个人实践行为相关联
Network,一个地方公共卫生系统,过度照顾社会经济地位较低的个人。
研究设计将涉及大型国家数据集(国家卫生和
营养检查调查; NHANES)用于目标 1 以及来自某人电子健康记录的本地数据集
目标 2 和 3 的卫生服务提供系统(旧金山健康网络)。目标 3 还将涉及对
当地初级保健提供者评估对相关指南的认识和对心血管风险的看法
给 CKD 患者。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CKD Progression From the Time of Estimated GFR-Based Waitlist Eligibility and Racial Disparities in Transplant Access.
从基于 GFR 的估计等候名单资格和移植机会的种族差异开始的 CKD 进展。
- DOI:
- 发表时间:2022-06
- 期刊:
- 影响因子:0
- 作者:Chu, Chi D;Powe, Neil R;Crews, Deidra C;Tuot, Delphine S
- 通讯作者:Tuot, Delphine S
Albuminuria testing and nephrology care among insured US adults with chronic kidney disease: a missed opportunity.
患有慢性肾病的美国成年人的蛋白尿检测和肾病护理:错失的机会。
- DOI:
- 发表时间:2022-11-24
- 期刊:
- 影响因子:0
- 作者:Chu CD;Powe NR;Shlipak MG;Scherzer R;Tummalapalli SL;Estrella MM;Tuot DS
- 通讯作者:Tuot DS
Completeness and quality of text paging for subspecialty consult requests.
专科咨询请求文本分页的完整性和质量。
- DOI:
- 发表时间:2021-08
- 期刊:
- 影响因子:5.1
- 作者:Chu, Chi D;Tuot, Delphine S;Harrison, James D;Duong, Jonathan;Luxenberg, Adam;Khanna, Raman R
- 通讯作者:Khanna, Raman R
Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019.
2012-2019 年美国按种族和民族划分的慢性肾脏病护理趋势。
- DOI:
- 发表时间:2021-09-01
- 期刊:
- 影响因子:13.8
- 作者:Chu, Chi D;Powe, Neil R;McCulloch, Charles E;Crews, Deidra C;Han, Yun;Bragg;Saran, Rajiv;Koyama, Alain;Burrows, Nilka R;Tuot, Delphine S;Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
- 通讯作者:Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.
患有蛋白尿的美国成人高血压患者使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。
- DOI:
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Chu, Chi D;Powe, Neil R;McCulloch, Charles E;Banerjee, Tanushree;Crews, Deidra C;Saran, Rajiv;Bragg;Morgenstern, Hal;Pavkov, Meda E;Saydah, Sharon H;Tuot, Delphine S;Centers for Disease Control and Prevention Chronic Kidney Di
- 通讯作者:Centers for Disease Control and Prevention Chronic Kidney Di
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chi Chu其他文献
Chi Chu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chi Chu', 18)}}的其他基金
Targeted Automated Nephrology e-Consultation for Diabetic Kidney Disease
糖尿病肾病有针对性的自动化肾病电子咨询
- 批准号:
10591976 - 财政年份:2023
- 资助金额:
$ 7.37万 - 项目类别:
相似国自然基金
年龄相关性黄斑变性治疗中双靶向药物递释策略及其机制研究
- 批准号:82301217
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
GNAS介导OPN4-PLCβ4-TRPC6/7通路调节自主感光视网膜神经节细胞在年龄相关性黄斑变性中的作用机制研究
- 批准号:82301229
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
无线供能边缘网络中基于信息年龄的能量与数据协同调度算法研究
- 批准号:62372118
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
跨尺度年龄自适应儿童头部模型构建与弥漫性轴索损伤行为及表征研究
- 批准号:52375281
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 7.37万 - 项目类别:
Identification of Prospective Predictors of Alcohol Initiation During Early Adolescence
青春期早期饮酒的前瞻性预测因素的鉴定
- 批准号:
10823917 - 财政年份:2024
- 资助金额:
$ 7.37万 - 项目类别:
Developing Real-world Understanding of Medical Music therapy using the Electronic Health Record (DRUMMER)
使用电子健康记录 (DRUMMER) 培养对医学音乐治疗的真实理解
- 批准号:
10748859 - 财政年份:2024
- 资助金额:
$ 7.37万 - 项目类别:
Identifying Disparities in Care of Rural Patients with Cardiac Implantable Electronic Devices
确定使用心脏植入电子设备的农村患者的护理差异
- 批准号:
10555010 - 财政年份:2023
- 资助金额:
$ 7.37万 - 项目类别:
Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
停止使用羟氯喹治疗老年狼疮病 (SHIELD)
- 批准号:
10594743 - 财政年份:2023
- 资助金额:
$ 7.37万 - 项目类别: